[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y: Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol; 2006 Sep;13(9):1254-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
  • Small-cell carcinoma of the prostate (SCCP) is a rare entity.
  • Many treatment modalities have been done, but thus far no uniform treatment has been clearly established.
  • We carried out combination chemotherapy with gemcitabine, docetaxel, and carboplatin (GDC) regimen (for two patients with refractory SCCP.
  • Case 1 involved a 53-year-old man diagnosed with SCCP after receiving hormone therapy for prostate cancer (stage D1).
  • Six cycles of GDC chemotherapy was applied.
  • Initially the primary site reduced according with a decline of neuro-specific enolase and with relief of the symptoms; however, bone disease occurred and he died of cancer 13 months after diagnosis of SCCP.
  • He underwent a biopsy and a huge prostate tumor showing SCCP was showed.
  • He had pelvic node metastases but no distant lesions, and received four cycles of GDC chemotherapy.
  • He was discharged after receiving subsequent radiotherapy and remained stable for a while; however, he died of possible drug-induced hepatitis.
  • This is the first report of chemotherapy with GDC against patients with SCCP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fatal Outcome. Humans. Male. Middle Aged. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / secondary. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984566.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Ishizu K, Tsushimi M, Shimajiri S, Hamada T, Sasaguri Y, Naito K: [Small cell carcinoma of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report]. Hinyokika Kiyo; 2002 Feb;48(2):97-100
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate successfully treated with combined chemotherapy and radiotherapy: a case report].
  • The prostate was enlarged, and the serum level of prostate specific antigen was within the normal range.
  • Under the diagnosis of benign prostatic hypertrophy, transurethral resection of the prostate was performed.
  • Unexpectedly, histopathological examination of the resected tissues revealed pure small cell carcinoma.
  • Pelvic radiotherapy combined with chemotherapy using cisplatin (CDDP) and etoposide (VP-16) was started according to the treatment for limited small cell cancer of the lung.
  • After four months, the prostate was reduced in size without any findings of metastases on computed tomography, and prostate biopsy revealed no viable cancer cells.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968736.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Yildirim Y, Akcay Y, Ozyilkan O, Celasun B: Prostate small cell carcinoma and skin metastases: a rare entity. Med Princ Pract; 2008;17(3):250-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate small cell carcinoma and skin metastases: a rare entity.
  • OBJECTIVES: To report a rare case of small cell carcinoma of the prostate with unusual skin metastasis.
  • Abdominal computed tomography scans revealed a prostatic mass invading the surrounding tissues and multiple perirectal, periprostatic, para-aortic and pericaval lymph nodes.
  • Needle biopsy specimens showed both small cell carcinoma and adenocarcinoma.
  • He was treated with combination chemotherapy: cisplatin and etoposide and bilateral orchiectomy.
  • After six cycles of the chemotherapy, disease progressed and the patient did not respond to salvage therapy; hence, palliative care was instituted.
  • During the follow-up, papillary lesions were observed in the scrotal skin; biopsy showed metastatic small cell carcinoma.
  • CONCLUSION: Small cell carcinoma of the prostate is an aggressive disease with a highly metastatic potential; but skin metastases are very uncommon.
  • It has poor prognosis despite therapy.
  • Management resembles that of small cell carcinoma of the lung.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / secondary. Prostatic Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18408396.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kim KH, Park SU, Jang JY, Park WK, Oh CK, Rha KH: A case of robot-assisted laparoscopic radical prostatectomy in primary small cell prostate cancer. Korean J Urol; 2010 Dec;51(12):882-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of robot-assisted laparoscopic radical prostatectomy in primary small cell prostate cancer.
  • Primary small cell carcinoma of the prostate is a rare and very aggressive disease with a poor prognosis, even in its localized form.
  • We managed a case of primary small cell carcinoma of the prostate.
  • The patient was treated with robot-assisted laparoscopic radical prostatectomy and adjuvant chemotherapy.
  • Herein we report this first case of robot-assisted laparoscopic radical prostatectomy performed in a patient with primary small cell carcinoma of the prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1992 Aug;65(776):726-8 [1382791.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):705-12 [16723847.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1118-20 [1717124.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):22-9 [17270662.001]
  • [Cites] Md Med J. 1997 Aug;46(7):353-6 [9260470.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):977-82 [2434204.001]
  • [Cites] Int Urol Nephrol. 1993;25(4):379-84 [8276566.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):65-71 [18162772.001]
  • [Cites] Urology. 1995 Nov;46(5):617-30 [7495110.001]
  • [Cites] Cancer. 1977 Aug;40(2):773-8 [196743.001]
  • (PMID = 21221211.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3016437
  • [Keywords] NOTNLM ; Prostatectomy / Robotics / Small cell carcinoma
  •  go-up   go-down


5. Yashi M, Suzuki K, Tokue A: [A case of giant small cell carcinoma of the prostate]. Hinyokika Kiyo; 2001 Jan;47(1):55-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of giant small cell carcinoma of the prostate].
  • Abdomino-pelvic CT revealed bilateral hydronephrosis, a giant prostate over 500 g in weight, and multiple para-aortic lymph node metastasis.
  • Histological diagnosis of the prostate was small cell neuroendocrine carcinoma.
  • The patient was treated with hormone-chemotherapy after successful treatment of the renal failure, but he died on the 74th hospital day.
  • Small cell carcinoma is known to have a high rate of malignancy and metastasis from an early stage.
  • Several giant prostatic tumors have been reported previously, but this case is considered to be the second gigantic small cell carcinoma in the Japanese literature.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Hydronephrosis / etiology. Lymphatic Metastasis. Male. Middle Aged. Phosphopyruvate Hydratase / blood. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235225.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


6. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab; 2010 Nov;21(11):691-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
  • Breast and prostate cancers are hormone-sensitive malignancies that afflict millions of women and men.
  • Blockade of the PRLR represents a novel treatment for patients with advanced breast or prostate cancer with limited therapeutic options.
  • Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Endocrinology. 2007 Jul;148(7):3089-101 [17412813.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33118-31 [17785459.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):236-48 [18172316.001]
  • [Cites] Endocr Rev. 2008 Feb;29(1):1-41 [18057139.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):131-45 [18253708.001]
  • [Cites] BMC Biotechnol. 2008;8:11 [18254957.001]
  • [Cites] J Biol Chem. 2008 Jul 4;283(27):19085-94 [18467331.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):241-50 [17955362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14533-8 [18779591.001]
  • [Cites] Breast Cancer Res. 2008;10(4):R68 [18681966.001]
  • [Cites] Bioorg Med Chem. 2009 Feb 1;17(3):1026-33 [18234500.001]
  • [Cites] Structure. 2009 Apr 15;17(4):489-98 [19368882.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1298-304 [19443905.001]
  • [Cites] Mod Pathol. 2009 Oct;22(10):1273-9 [19633648.001]
  • [Cites] Growth Horm IGF Res. 2002 Apr;12(2):126-36 [12175650.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jan;95(1):271-9 [19897676.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3583-93 [10589775.001]
  • [Cites] Ann Surg Oncol. 2000 May;7(4):305-11 [10819372.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33937-44 [10938266.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):767-77 [11159849.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [11259830.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1217-22 [11290538.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):463-5 [11291087.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6098-104 [11507059.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] Mol Hum Reprod. 2002 Jul;8(7):606-11 [12087074.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5047-55 [12140755.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1131-4 [12168912.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):R91-107 [20071456.001]
  • [Cites] Mol Cell Endocrinol. 2002 Nov 29;197(1-2):153-65 [12431808.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:454-8 [12485910.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 [12574200.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):369-78 [12750740.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):241-52 [12825859.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4955-66 [12960074.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4666-73 [14581335.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23 [15196705.001]
  • [Cites] Lancet. 1976 Aug 7;2(7980):279-82 [59853.001]
  • [Cites] Cancer. 1977 Apr;39(4):1693-9 [856451.001]
  • [Cites] Am J Clin Pathol. 1985 Dec;84(6):687-96 [3878077.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Dec;24(12):1851-3 [3065085.001]
  • [Cites] Lab Invest. 1993 Mar;68(3):354-60 [8450651.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cell Growth Differ. 1995 Apr;6(4):477-83 [7794815.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):3094-6 [7559904.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):639-69 [8969972.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):243-53 [9266104.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3692-9 [9360527.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5555-60 [9389544.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):202-11 [9583737.001]
  • [Cites] Endocr Rev. 1998 Aug;19(4):365-96 [9715372.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):863-70 [10079264.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):109-15 [15666390.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5863-8 [16115927.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Oct;15(10):1257-67 [16989600.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] J Biomol Screen. 2006 Oct;11(7):864-9 [16973922.001]
  • [Cites] Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):297-307 [17010651.001]
  • [Cites] Oncogene. 2006 Dec 7;25(58):7565-76 [16785991.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D298-300 [17135201.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):3262-72 [17130123.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8422-33 [20053995.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8003-12 [20080972.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):369-77 [19377875.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1959-72 [20167868.001]
  • [Cites] Appl Microbiol Biotechnol. 2010 Jun;87(1):75-86 [20396881.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):481-93 [20233708.001]
  • [Cites] Anal Biochem. 2010 Aug;403(1-2):94-101 [20382104.001]
  • [Cites] J Biol Chem. 2010 Jun 25;285(26):20022-30 [20427283.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):121-41 [17068222.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Drugs. 2007;67(9):1329-41 [17547474.001]
  • (PMID = 20846877.001).
  • [ISSN] 1879-3061
  • [Journal-full-title] Trends in endocrinology and metabolism: TEM
  • [ISO-abbreviation] Trends Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES016803; United States / NCI NIH HHS / CA / R01 CA096613; United States / NCI NIH HHS / BC / Z01 BC005725; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R21 ES016803; United States / NCI NIH HHS / CA / CA096613; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Prolactin
  • [Other-IDs] NLM/ NIHMS237492; NLM/ PMC2967606
  •  go-up   go-down


7. Sakai H, Tsuruta T, Wajiki M: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2004 Apr;50(4):269-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate: a case report].
  • He had undergone anti-androgen therapy for prostate cancer for 8 months at another hospital.
  • His serum prostate specific antigen (PSA) level was 14.4 ng/ml.
  • We performed a prostate biopsy and identified poorly differentiated adenocarcinoma with Gleason score 4 + 5.
  • After 4 months, his serum PSA level increased to 24.8 ng/ml, and we started maximum androgen blockade therapy using additional luteinizing hormone-releasing hormone (LH-RH) analogue.
  • Subsequently, although his serum PSA level declined favorably, his condition worsened rapidly and he died at 16 months after the diagnosis.
  • The autopsy pathology of his prostate revealed small cell carcinoma.
  • We reviewed the initial biopsy specimens and found both small cell carcinoma and adenocarcinoma histologic types of prostate cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Gonadotropin-Releasing Hormone / therapeutic use. Humans. Male. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15188622.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S: Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol; 2009 Oct;14(5):468-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
  • We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis.
  • In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered.
  • Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed efficacy in targeting the small cell carcinoma.
  • Small cell carcinoma of the prostate complicated with meningeal carcinomatosis was diagnosed.
  • A different chemotherapy regimen was then administered, consisting of a combination of carboplatin plus irinotecan, which is one of the most common first-line treatments for extensive-stage small cell lung carcinoma.
  • From day 20 after the initiation of this therapy, he gradually recovered from the signs of meningeal irritation, and brain MRI showed nearly normal findings; also, the serum level of ProGRP was reduced.
  • In conclusion, we report the efficacy of combined treatment with carboplatin plus irinotecan for small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
  • Because this clinical condition is extremely rare, a gold standard treatment has yet to be established.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Meningeal Carcinomatosis / drug therapy. Neoplasm Recurrence, Local. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carboplatin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Peptide Fragments / blood. Recombinant Proteins / blood. Spinal Puncture. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2002 Sep;37(3):319-23 [12234702.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):804-7 [1311395.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3072-80 [12118020.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):333-8 [12781433.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2122-6 [11391593.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):80-91 [18784279.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):162-9 [17579629.001]
  • [Cites] Int J Urol. 2006 Sep;13(9):1254-8 [16984566.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3281-4 [18591564.001]
  • [Cites] Urology. 1992 May;39(5):411-6 [1315995.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2728-30 [6722732.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):935-7 [1311396.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1620-7 [3021922.001]
  • [Cites] Mol Interv. 2003 Mar;3(2):90-105, 51 [14993430.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1168-71 [18309954.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):365-70 [17011068.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):169-72 [18463964.001]
  • [Cites] Biol Pharm Bull. 1999 Apr;22(4):428-31 [10328568.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] Clin Lung Cancer. 2008 Jan;9(1):35-8 [18282356.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • (PMID = 19856060.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R, Kuten A: Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci; 2008 Dec;336(6):478-88
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network.
  • Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage.
  • Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy.
  • Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form.
  • Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly.
  • Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.
  • [MeSH-major] Carcinoma, Small Cell / etiology. Carcinoma, Small Cell / therapy. Diagnosis, Differential. Prostatic Neoplasms / etiology. Prostatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092321.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Alapont Alacreu JM, Montaner Ramírez MJ, Pontones Moreno JL, Valls Blasco F, Vera-Sempere FJ, Jiménez-Cruz JF: [Small cell carcinoma of the prostate]. Actas Urol Esp; 2002 Sep;26(8):585-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate].
  • [Transliterated title] Carcinoma prostático de células pequeñas.
  • Pure small cell carcinoma of the prostate is rare (less than 1% of all prostatic neoplasm).
  • Small cell carcinomas of the prostate are a heterogeneous group of tumors, a number of them have neuroendocrine differentiation and are highly aggressive, commonly with visceral metastases at time of diagnosis.
  • Complete temporary remission has been reported with chemotherapy but this tumor has a poor prognosis.
  • The median overall survival from the time of diagnosis is between 5-17.5 months.
  • We report 2 new cases of small cell carcinoma of the prostate and a review of the literature.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12448178.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


11. Katou M, Soga N, Onishi T, Arima K, Sugimura Y: Small cell carcinoma of the prostate treated with amrubicin. Int J Clin Oncol; 2008 Apr;13(2):169-72
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the prostate treated with amrubicin.
  • We describe the use of amrubicin hydrochloride to treat small cell carcinoma of the prostate in a 23-year-old man.
  • The pathological diagnosis was small cell carcinoma originating in the prostate, based on positive immunohistochemical staining for neuron-specific enolase, synaptophysin, and myoglobulin; and negative staining for CD3e, CD20, leukocyte common antigen, and CD99.
  • The first induction chemotherapy consisted of amrubicin 35 mg/m(2) (days 1, 2, 3, monthly).
  • Five months after the induction of chemotherapy, the patient suffered respiratory arrest and died.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2006 Mar;24(2):151-8 [16502350.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Mar;33(3):373-5 [16531722.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(3-4):134-40 [10235466.001]
  • [Cites] J UOEH. 2006 Mar 1;28(1):75-84 [16541742.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):179-87 [11782376.001]
  • [Cites] J Am Board Fam Pract. 2003 Jul-Aug;16(4):343-4 [12949037.001]
  • [Cites] Urology. 1992 May;39(5):411-6 [1315995.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):935-7 [1311396.001]
  • [Cites] BJU Int. 2006 Apr;97(4):711-5 [16536759.001]
  • [Cites] Arch Pathol Lab Med. 1988 Nov;112(11):1100-5 [2460064.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jan;33(1):24-8 [16410693.001]
  • [Cites] Ther Drug Monit. 2006 Feb;28(1):76-82 [16418698.001]
  • (PMID = 18463964.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 93N13LB4Z2 / amrubicin
  •  go-up   go-down


12. Alshaikh OM, Al-Mahfouz AA, Al-Hindi H, Mahfouz AB, Alzahrani AS: Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer. Endocr Pract; 2010 Mar-Apr;16(2):249-54
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer.
  • METHODS: We describe the clinical presentation and management of a case of Cushing syndrome attributable to ectopic ACTH secretion from small cell cancer of the prostate.
  • RESULTS: In a 70-year-old man with hypertension and diabetes, congestive heart failure developed.
  • Transurethral biopsy of the prostate showed features of small cell prostate cancer.
  • Hormonal evaluation revealed a high urine free cortisol excretion of 6,214.5 microg/d (reference range, 36 to 137), confirming the diagnosis of Cushing syndrome.
  • An overnight high-dose (8 mg orally) dexamethasone suppression test was positive (serum cortisol levels were 43.2 and 41 microg/dL before and after suppression, respectively), and magnetic resonance imaging of the pituitary gland disclosed no abnormalities.
  • A prostate biopsy specimen showed small cell prostate cancer with positive staining for ACTH.
  • He received 1 cycle of chemotherapy (etoposide and cisplatin), but he died 6 months later as a result of sepsis.
  • CONCLUSION: Small cell prostate cancer is a rare subtype that can be associated with ectopic secretion of ACTH and severe Cushing syndrome.
  • With this subtype of prostate cancer, Cushing syndrome should be considered and appropriately managed.
  • [MeSH-major] Adrenocorticotropic Hormone / metabolism. Carcinoma, Small Cell / complications. Cushing Syndrome / etiology. Cushing Syndrome / metabolism. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061271.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


13. Raja M, Akhtar S, El Weshi A, Maghfoor I: Extrapulmonary small cell carcinoma (EPSCC): Retrospective review from a single institution. J Clin Oncol; 2004 Jul 15;22(14_suppl):6108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small cell carcinoma (EPSCC): Retrospective review from a single institution.
  • We therefore decided to review our institution's experience with EPSCC with special emphasis on treatment considerations.
  • Lung disease at presentation and Merkel cell carcinoma of skin were excluded.
  • Sites of origin were esophagus 7, cervix 6, parotid gland, lacrimal gland, urinary bladder, pancreas, and anal canal 2 each, and prostate 1.
  • Initial therapy consisted of chemotherapy in 11, surgery in 6, radiation therapy in 6, and no treatment in 1.
  • Fourteen patients received chemotherapy (including 11 as initial treatment).
  • Chemotherapy regimens included etoposide/platinum in 8, etoposide combinations in 2, cytoxan/doxorubicin/vincristine/etoposide in 4.
  • At the completion of all therapy complete response was observed in 9, partial response in 3, stable disease in 1, progressive disease in 4 and not evaluable in 7.
  • Four of these were treated with combination of chemotherapy and local treatment.
  • Patients presenting with localized disease should be treated aggressively with combined modality therapy including chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Colecchia M, Dagrada G, Poliani PL, Messina A, Pilotti S: Primary primitive peripheral neuroectodermal tumor of the prostate. Immunophenotypic and molecular study of a case. Arch Pathol Lab Med; 2003 Apr;127(4):e190-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary primitive peripheral neuroectodermal tumor of the prostate. Immunophenotypic and molecular study of a case.
  • A case of primitive peripheral neuroectodermal tumor arising in the prostate gland of a 31-year-old man and first diagnosed through a biopsy is reported.
  • Microscopically, the tumor was made up of solid nests and sheets of small round cells, and it was difficult to distinguish the neoplasm from other small round cell tumors, such as small cell carcinoma, rhabdomyosarcoma, or malignant lymphoma.
  • The neoplasm was excised by a radical surgical procedure preceded by chemotherapy and radiation therapy.
  • The morphologic diagnosis of the prostatectomy specimen was complemented by molecular analysis performed on viable microdissected tissue obtained from formalin-fixed, paraffin-embedded tumor sections.
  • Polymerase chain reaction and sequencing assessment showed the presence of EWS/FLI1 type 2 chimeric transcript, confirming the diagnosis of peripheral primitive neuroectodermal tumor.
  • To our knowledge, this is the first description of a primary peripheral primitive neuroectodermal tumor in the prostate gland.
  • [MeSH-major] Cytogenetic Analysis / methods. Immunophenotyping / methods. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Neuroectodermal Tumors, Primitive, Peripheral / genetics. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12683899.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down


15. Ciszewski A, Shackleton D, Beer TM: Long-term remission of metastatic small cell carcinoma of the prostate. Urology; 2008 Mar;71(3):546.e3-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of metastatic small cell carcinoma of the prostate.
  • Metastatic small cell carcinoma of the prostate portends a poor prognosis.
  • We report a case of one of the longest known surviving patients in continuous complete remission with metastatic small cell carcinoma of the prostate and review the available literature reporting longer-term survival in this condition.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Remission Induction. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342209.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 5
  •  go-up   go-down


16. López Cubillana P, Martínez Barba E, Prieto A, Server Pastor G, Sola J, Nicolás JA, García Hernández JA, Gómez G, Martínez Pertusa P, Pérez Albacete M, Bañón V, Valdelvira P, Guardiola A, Castillo D, Cao E, Alonso JD: Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. Urol Int; 2001;67(3):209-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications.
  • BACKGROUND: Any carcinoma of prostatic origin which is not an acinary adenocarcinoma of the prostate is considered to be an atypical carcinoma.
  • One member of this group of atypical prostatic tumors is the oat-cell carcinoma, or small cell carcinoma (SCC) of the prostate.
  • This variety of carcinoma constitutes the histologic basis of <1% of all prostatic neoplasms.
  • METHODS: Between 1992 and 1997, four patients were diagnosed with SCC of the prostate at our hospital.
  • In 3 of the 4 cases, the histopathological diagnosis was pure SCC, and in the 4th case there was a component of prostatic adenocarcinoma associated with the SCC.
  • At the time of diagnosis, extracapsular extension of the tumor was present in all 4 cases, with T3 or higher stages in all of them (T(3A)N(0)M(1), T(3A)N(0)M(0), T(3B)N(0)M(1), and T(4)N(0)M(0)).
  • They were all offered systemic chemotherapy with cyclophosphamide (1 g/m(2)), doxorubicin (50 mg/m(2)) and vincristine (1.2 mg/m(2)).
  • This therapeutic protocol was carried out in only 2 cases.
  • RESULTS: Survival was <1 year in the 3 patients with pure SCC, and the patient with a mixed tumor is alive with detectable disease 9 months after diagnosis.
  • CONCLUSIONS: This poor vital prognosis in SCC stresses the need for early diagnosis a timely and appropriate therapeutic intervention in this condition.
  • [MeSH-major] Carcinoma, Small Cell. Prostatic Neoplasms

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • [CommentIn] Urol Int. 2002;69(2):166-8 [12187054.001]
  • (PMID = 11598447.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Anderson CR, McNiel EA, Gillette EL, Powers BE, LaRue SM: Late complications of pelvic irradiation in 16 dogs. Vet Radiol Ultrasound; 2002 Mar-Apr;43(2):187-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When external beam radiation therapy is administered to the pelvis, normal tissues irradiated may include the colon, small intestine, urethra, bladder, bone, and spinal cord.
  • Medical records of all dogs treated with curative intent external beam radiation therapy to the pelvic region between 1993 and 1999 were reviewed.
  • Patients with follow-up longer than 9 months or any patient that developed late complications earlier than 9 months were evaluated.
  • Diseases treated included transitional cell carcinoma of the bladder, transitional cell carcinoma of the prostate, and anal sac apocrine gland adenocarcinoma.
  • Four dose/fractionation schemes were used: 49.5 Gy in 3.3 Gy fractions, 54 Gy in 3.0 Gy fractions, 54 Gy in 2.7 Gy fractions, and 18 Gy intraoperative radiation therapy followed by 43 Gy external beam radiation therapy in 2.9 Gy fractions.
  • Implantable chemotherapy in the form of an OPLA-Pt sponge was used in six dogs as a radiation potentiator.
  • All dogs with severe late effects received 3 or 3.3 Gy per fraction, and 80% received radiation potentiators.
  • In the seven dogs that received 2.7 Gy or 2.9 Gy per fraction, late effects were classified as none (n = 5), mild colitis (n = 1), and moderate colitis (n = 1).
  • Radiation therapy can be administered to the pelvic region with a minimal risk of late effects to the colon by giving smaller doses per fraction and avoiding systemic radiation potentiators.
  • [MeSH-major] Carcinoma, Transitional Cell / veterinary. Dog Diseases / radiotherapy. Neoplasms / veterinary. Radiation Injuries / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11954816.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Shan D, Chen L, Njardarson JT, Gaul C, Ma X, Danishefsky SJ, Huang XY: Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice. Proc Natl Acad Sci U S A; 2005 Mar 8;102(10):3772-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of these readily accessible compounds nearly completely inhibits lung metastasis of highly metastatic mammary carcinoma cells.
  • Treatment of tumor cells with core macroketone and core macrolactam blocks Rac activation, lamellipodia formation, and cell migration, suggesting that these chemical compounds interfere with the invasion step of the metastatic process.
  • These compounds also inhibit the migration of human metastatic breast cancer cells, prostate cancer cells, and colon cancer cells but not normal mammary-gland epithelial cells, fibroblasts, and leukocytes.
  • These data demonstrate that the macroketone and macrolactam core structures are specific small-molecule inhibitors of tumor metastasis.
  • These compounds or their analogues could potentially be used in cancer-therapy strategies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Lactones / therapeutic use. Macrolides / therapeutic use. Piperidones / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Female. Humans. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Neoplasm Metastasis. rac GTP-Binding Proteins / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antibiot (Tokyo). 2000 Oct;53(10):1130-6 [11132958.001]
  • [Cites] J Antibiot (Tokyo). 2000 Oct;53(10):1228-30 [11132973.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):259-66 [11231575.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(3-4):I-XI, 193-383 [11394186.001]
  • [Cites] J Antibiot (Tokyo). 2002 Feb;55(2):141-6 [12002995.001]
  • [Cites] Dev Cell. 2002 Jun;2(6):733-44 [12062086.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] J Am Chem Soc. 2004 Feb 4;126(4):1038-40 [14746469.001]
  • [Cites] J Leukoc Biol. 2004 Aug;76(2):322-32 [15123779.001]
  • [Cites] J Am Chem Soc. 2004 Sep 15;126(36):11326-37 [15355116.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1399-405 [1540948.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1486-93 [9537252.001]
  • [Cites] J Cell Sci. 1998 Aug;111 ( Pt 16):2433-43 [9683637.001]
  • (PMID = 15728385.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lactones; 0 / Macrolides; 0 / Piperidones; 0 / migrastatin; EC 3.6.5.2 / rac GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC553334
  •  go-up   go-down


19. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol; 2002 Jul 15;20(14):3072-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
  • PURPOSE: To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa.
  • PATIENTS AND METHODS: Patients with SCPCa (pure or mixed), measurable disease, good organ function, and no prior treatment with doxorubicin, etoposide, or cisplatin were treated every 4 weeks with doxorubicin 50 mg/m(2) as a 24-hour intravenous (IV) infusion followed by etoposide 120 mg/m(2)/d and cisplatin 25 mg/m(2)/d IV on days 2 to 4.
  • Twenty-nine (81%) of 36 patients had prior hormonal therapy.
  • Study patients had visceral metastases, lytic bone disease, and relatively low serum prostate-specific antigen (PSA).
  • Median time to progression and overall survival time were 5.8 months and 10.5 months, respectively.
  • Performance status, serum albumin, and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) were predictors of survival.
  • Improvement in therapy will come from understanding the biology of SCPCa progression and integrating new targeted therapies into the treatment of SCPCa.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Infusions, Intravenous. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12118020.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Yoshida T, Nishimura K, Uemura M, Nakagawa K, Harada Y, Kanno N, Miyoshi S, Kawano K: [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness]. Hinyokika Kiyo; 2006 Nov;52(11):891-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
  • Case 1 : A 76-year-old man with a chief complaint of dysuria had an elevated prostate specific antigen (PSA) level of 24.9.
  • He underwent a transperineal needle biopsy of the prostate, and the histopathological diagnosis was prostatic small cell carcinoma.
  • He started receiving hormonal therapy.
  • After three months of hormonal therapy, the multiple lung metastases disappeared.
  • Thereafter, the serum PSA level and the tumor volume increased and he died 12 months from the start of therapy.
  • Transperineal prostate biopsy revealed prostatic small cell carcinoma.
  • The cancer was clinically diagnosed as T3bN1M1, and hormonal therapy was started.
  • Subsequently, although his serum PSA level declined, his condition worsened rapidly and he died five months after the start of therapy.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Carcinoma, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17176877.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


21. Candura SM, Fonte R, Cantale G, Paolotti D, Biscaldi G: [Small cell carcinoma of the prostate. Description of a case]. Recenti Prog Med; 2000 Nov;91(11):567-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate. Description of a case].
  • [Transliterated title] Carcinoma a piccole cellule della prostata. Descrizione di un caso.
  • The case of a 73-year-old man with metastatic small cell carcinoma (SCC) of the prostate is described.
  • Seric neuron-specific enolase (NSE) was enhanced (75.4 ng/mL), while the prostate-specific antigen (PSA) was in the normal range.
  • Therapy with etoposide and carboplatin induced a temporary partial remission, with fairly good quality of life and decrease of the NSE levels (down to 15.0 ng/mL).
  • The patient died approximately 12 months after the initial diagnosis.
  • Treatment is problematic, however chemotherapy may prolong survival allowing, at least temporarly, an acceptable life quality.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11125949.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


22. Kageyama S, Narita M, Kim CJ, Hanada E, Sakano Y, Iwaki H, Yoshiki T, Okada Y: [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan]. Hinyokika Kiyo; 2006 Oct;52(10):809-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan].
  • Small cell carcinoma (SCC) originating from the prostate is rare.
  • We report three cases of SCC of the prostate.
  • Case 1: A 29-year-old man with large pelvic mass and pelvic lymph node metastases was diagnosed as having pure SCC of the prostate.
  • However, the disease recurred immediately, and he died of disease 17 months after diagnosis.
  • Although cystoprostatectomy combined with pre- and post-operative chemotherapy ended with no evidence of disease, he died after 16 months because of multiple metastases and local recurrence.
  • Case 3: A 73-year-old man was diagnosed as having SCC and poorly differentiated adenocarcinoma of the prostate simultaneously.
  • Chemo-endocrine therapy and pelvic irradiation were performed, achieving partial remission.
  • However, he developed multiple distant metastases, and died of disease 15 months after diagnosis.
  • Survival did not differ in patients with pure SCC or mixed glandular and small cell carcinoma.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131874.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y: Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer; 2003 May 10;104(6):782-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
  • Small cell carcinoma of the prostate (SCCP), although relatively rare, is the most aggressive variant of prostate cancer, currently with no successful treatment.
  • It was therefore tempting to evaluate the response of this violent malignancy and its bone lesions to Pd-Bacteriopheophorbide (TOOKAD)-based photodynamic therapy (PDT), already proven by us to efficiently eradicate other aggressive non-epithelial solid tumors.
  • TOOKAD is a novel bacteriochlorophyll-derived, second-generation photosensitizer recently, developed by us for the treatment of bulky tumors.
  • This photosensitizer is endowed with strong light absorbance (epsilon(0) approximately 10(5) mol(-1) cm(-1)) in the near infrared region (lambda=763nm), allowing deep tissue penetration.
  • The sensitizer clears rapidly from the circulation within a few hours and does not accumulate in tissues, which is compatible with the treatment of localized tumor and isolated metastases.
  • Briefly, male CD1-nude mice were grafted with the human SCCP (WISH-PC2) in 3 relevant anatomic locations: subcutaneous (representing tumor mass), intraosseous (representing bone metastases) and orthotopically within the murine prostate microenvironment.
  • The study with this model suggests that TOOKAD-based PDT can reach large tumors and is a feasible, efficient and well-tolerated approach for minimally invasive treatment of local and disseminated SCCP.
  • [MeSH-major] Bacteriochlorophylls / therapeutic use. Carcinoma, Small Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bone Diseases / pathology. Chromogranin A. Chromogranins / blood. Humans. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Mice. Mice, Nude. Models, Animal. Neoplasm Transplantation. Transplantation, Heterologous. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12640688.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / Chromogranin A; 0 / Chromogranins; 0 / Photosensitizing Agents; 0 / palladium-bacteriopheophorbide
  •  go-up   go-down


24. Benchekroun A, Nouini Y, Zannoud M, Kasmaoui el H, Jira M, Iken A: [Small cell carcinoma of the prostate: a case report]. Ann Urol (Paris); 2002 Oct;36(5):314-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the prostate: a case report].
  • [Transliterated title] Carcinome à petites cellules de la prostate: à propos d'un cas.
  • Pure small cells carcinoma of the prostate is a rare tumour with a pejorative forecast.
  • We report a case of neuroendocrine small cells carcinoma developed at a 68 years old patient.
  • The patient was treated by chemotherapy associating etoposide and cisplatinium and external radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12481622.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement